ATAIAtaiBeckley Inc.

HealthcareUSD
$7.38

Price

$7.38+78%1Y
1M+2.9%1Y+78%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average
5/10
Value83
Quality8
Momentum77
Growth15
Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve. Mental health disorders are highly prevalent and estimated to affect more than one billion people globally.

In the company’s own words · 10-K filed Mar 6, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$1.49B
1Y Return+78%
5Y Return-53%

AtaiBeckley Inc. (ATAI) reported revenue of $954K in Q1 2026 (quarter ended March 31, 2026). That came with net loss of $30M. For the full year FY2025, revenue was $4.1M (+1228% year on year) and net income −$660M.

Biotechnology

Ranks #116 of 145 by Smart Score

Compare peers
SRPT-4.1%
Sarepta Therapeutics, Inc.
FTRE+4.1%
Fortrea Holdings Inc.
URGN-2.9%
UroGen Pharma Ltd.
MLTX-0.05%
MoonLake Immunotherapeutics
VIR-0.70%
Vir Biotechnology, Inc.
AKTS+8.5%
Aktis Oncology, Inc.